Zacks Investment Research lowered shares of Novartis (NYSE:NVS) from a hold rating to a sell rating in a research note issued to investors on Tuesday.
According to Zacks, “Novartis is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin-off or an initial public offering. The company believes that the Alcon division has revived well for now even though a separation via capital markets will create value for shareholders. The loss of patent protection for some of the key drugs in Novartis’ portfolio is a cause of concern. Moreover, Kisqali’s uptake has been slow. Shares of the company have underperformed the industry in the last three months. Nevertheless, Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu, and Kisqali. The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis given the potential in the CAR T therapy space.”
Several other equities research analysts also recently commented on NVS. Nord/LB restated a neutral rating on shares of Novartis in a research note on Tuesday. JPMorgan Chase & Co. restated a neutral rating on shares of Novartis in a research note on Tuesday, September 26th. Barclays downgraded shares of Novartis from an equal weight rating to an underweight rating in a research report on Wednesday, October 25th. Leerink Swann upped their price target on shares of Novartis from $89.00 to $91.00 and gave the stock a market perform rating in a research report on Monday, October 23rd. Finally, Bank of America downgraded shares of Novartis from a neutral rating to an underperform rating in a research report on Wednesday, December 6th. Five research analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. Novartis currently has an average rating of Hold and an average price target of $85.32.
Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The company had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. During the same quarter in the previous year, the company earned $1.23 EPS. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. sell-side analysts expect that Novartis will post 4.77 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Beach Investment Management LLC. acquired a new position in Novartis during the 2nd quarter valued at about $5,592,000. Buckingham Asset Management LLC acquired a new position in Novartis during the 2nd quarter valued at about $1,331,000. Schulhoff & Co. Inc. lifted its position in Novartis by 4.3% during the 2nd quarter. Schulhoff & Co. Inc. now owns 8,323 shares of the company’s stock valued at $694,000 after purchasing an additional 343 shares during the period. Brookstone Capital Management lifted its position in Novartis by 1.1% during the 2nd quarter. Brookstone Capital Management now owns 2,930 shares of the company’s stock valued at $245,000 after purchasing an additional 31 shares during the period. Finally, Cambridge Investment Research Advisors Inc. lifted its position in Novartis by 2.1% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 39,530 shares of the company’s stock valued at $3,300,000 after purchasing an additional 804 shares during the period. Institutional investors and hedge funds own 10.85% of the company’s stock.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Novartis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis and related companies.